Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15155836 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Lo RK, Wong YH (2004) Signal transducer and activator of transcription 3 activation by the delta-opioid receptor via Galpha14 involves multiple intermediates. Mol Pharmacol 65, 1427-39 15155836
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y705-p - STAT3 (human)
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  293 (epithelial), HEL (erythroid)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DPDPE DOR-1 (human), G-alpha 14 (human) increase
PTX DPDPE DOR-1 (human), G-alpha 14 (human) no effect upon treatment-induced increase
Raf1 kinase inhibitor I DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
U73122 DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
AG490 DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
calphostin C DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
PP2 DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
G-alpha 14 (human) increase constitutively active
KN-62 G-alpha 14 (human) inhibit treatment-induced increase
U73122 G-alpha 14 (human) inhibit treatment-induced increase
SB203580 G-alpha 14 (human) no effect upon treatment-induced increase
AG490 G-alpha 14 (human) inhibit treatment-induced increase
WHI-P131 G-alpha 14 (human) inhibit treatment-induced increase
PP2 G-alpha 14 (human) inhibit treatment-induced increase
calphostin C G-alpha 14 (human) inhibit treatment-induced increase
U0126 G-alpha 14 (human) inhibit treatment-induced increase
SB202190 G-alpha 14 (human) no effect upon treatment-induced increase
SB203580 G-alpha 14 (human) no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced
 Effect of modification (process):  transcription, altered

S727-p - STAT3 (human)
Orthologous residues
STAT3 (human): S727‑p, STAT3 iso2 (human): S726‑p, STAT3 (mouse): S727‑p, STAT3 iso2 (mouse): , STAT3 iso3 (mouse): S726‑p, STAT3 (rat): S727‑p, STAT3 (cow): S727‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  293 (epithelial), HEL (erythroid)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DPDPE DOR-1 (human), G-alpha 14 (human) increase
PTX DPDPE DOR-1 (human), G-alpha 14 (human) no effect upon treatment-induced increase
Raf1 kinase inhibitor I DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
U73122 DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
AG490 DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
calphostin C DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
PP2 DPDPE DOR-1 (human), G-alpha 14 (human) inhibit treatment-induced increase
G-alpha 14 (human) increase expression of constitutively active G-alpha14
KN-62 G-alpha 14 (human) inhibit treatment-induced increase
U73122 G-alpha 14 (human) inhibit treatment-induced increase
AG490 G-alpha 14 (human) inhibit treatment-induced increase
WHI-P131 G-alpha 14 (human) inhibit treatment-induced increase
PP2 G-alpha 14 (human) inhibit treatment-induced increase
calphostin C G-alpha 14 (human) inhibit treatment-induced increase
U0126 G-alpha 14 (human) inhibit treatment-induced increase
SB202190 G-alpha 14 (human) no effect upon treatment-induced increase
SB203580 G-alpha 14 (human) no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced
 Effect of modification (process):  transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.